JP2024523559A - アルドステロン合成酵素阻害剤を使用する方法 - Google Patents

アルドステロン合成酵素阻害剤を使用する方法 Download PDF

Info

Publication number
JP2024523559A
JP2024523559A JP2023579554A JP2023579554A JP2024523559A JP 2024523559 A JP2024523559 A JP 2024523559A JP 2023579554 A JP2023579554 A JP 2023579554A JP 2023579554 A JP2023579554 A JP 2023579554A JP 2024523559 A JP2024523559 A JP 2024523559A
Authority
JP
Japan
Prior art keywords
compound
dose
study
treatment
visit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523559A5 (https=
Inventor
ボンド，メアリー
マーフィー，ブライアン
ピアース，キャサリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincor Pharma Inc
Original Assignee
Cincor Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincor Pharma Inc filed Critical Cincor Pharma Inc
Publication of JP2024523559A publication Critical patent/JP2024523559A/ja
Publication of JP2024523559A5 publication Critical patent/JP2024523559A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023579554A 2021-06-24 2022-06-24 アルドステロン合成酵素阻害剤を使用する方法 Pending JP2024523559A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163214521P 2021-06-24 2021-06-24
US63/214,521 2021-06-24
US202163290364P 2021-12-16 2021-12-16
US63/290,364 2021-12-16
PCT/US2022/073148 WO2022272300A1 (en) 2021-06-24 2022-06-24 Methods of using aldosterone synthase inhibitors

Publications (2)

Publication Number Publication Date
JP2024523559A true JP2024523559A (ja) 2024-06-28
JP2024523559A5 JP2024523559A5 (https=) 2025-06-23

Family

ID=84545863

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579554A Pending JP2024523559A (ja) 2021-06-24 2022-06-24 アルドステロン合成酵素阻害剤を使用する方法

Country Status (10)

Country Link
US (1) US20240277698A1 (https=)
EP (1) EP4358959A4 (https=)
JP (1) JP2024523559A (https=)
KR (1) KR20240035483A (https=)
AU (2) AU2022299103B2 (https=)
BR (1) BR112023027025A2 (https=)
CA (1) CA3223211A1 (https=)
IL (1) IL309428A (https=)
MX (1) MX2023015121A (https=)
WO (1) WO2022272300A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024310688A1 (en) * 2023-06-29 2026-01-29 AstraZeneca Ireland Limited Crystal form of baxdrostat, and preparation method therefor and use thereof
CN121712504A (zh) * 2023-07-27 2026-03-20 矿物疗法公司 用洛伦司他及两种或更多种降压药的组合治疗高血压的方法
TW202525278A (zh) * 2023-12-15 2025-07-01 愛爾蘭商阿斯特捷利康愛爾蘭有限公司 治療慢性腎病及高血壓之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4777896A (en) * 1995-02-10 1996-08-27 G.D. Searle & Co. Use of low dose amount of spironolactone for treatment of cardiovascular disease
US20070196510A1 (en) * 2006-02-17 2007-08-23 Gerber Michael J Method for treating resistant hypertension
US9353081B2 (en) * 2011-09-23 2016-05-31 Hoffmann-La Roche Inc. Bicyclic dihydroquinoline-2-one derivatives

Also Published As

Publication number Publication date
EP4358959A1 (en) 2024-05-01
WO2022272300A1 (en) 2022-12-29
AU2022299103A1 (en) 2024-01-25
KR20240035483A (ko) 2024-03-15
IL309428A (en) 2024-02-01
AU2022299103B2 (en) 2025-12-18
US20240277698A1 (en) 2024-08-22
AU2026201954A1 (en) 2026-04-02
EP4358959A4 (en) 2025-05-14
CA3223211A1 (en) 2022-12-29
MX2023015121A (es) 2024-04-16
BR112023027025A2 (pt) 2024-03-12

Similar Documents

Publication Publication Date Title
CA2879548C (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
JP2024523559A (ja) アルドステロン合成酵素阻害剤を使用する方法
JP2010518169A (ja) 心血管疾患の処置のためのラノラジンの使用
TWI866427B (zh) 雌激素受體降解劑之給藥方案
CN105193807A (zh) 用于治疗急性躁狂的氨甲酰基-环己烷类
JP2025508069A (ja) アチカプラントを含む組成物
US20260041679A1 (en) Method of treating hypertension with the aldosterone synthase inhibitor baxdrostat
WO2021097038A1 (en) Novel dosage forms of rofecoxib and related methods
JP2025111453A (ja) 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン
JP2022075670A (ja) ネコの全身性疾患の予防又は治療用アンジオテンシンｉｉ受容体拮抗薬
JP2011511844A (ja) 心血管疾患の処置のためのラノラジンの使用
CN119421712A (zh) 用于多发性硬化和重症肌无力的治疗性酪氨酸激酶抑制剂
JP2025514817A (ja) 胃不全麻痺を処置するための重水素化ドンペリドン
CN117545482A (zh) 使用醛固酮合酶抑制剂的方法
WO2025038481A1 (en) Vepdegestrant dosage regimen in cyp3a-inducer treatment in cancer
JP2022521208A (ja) うつ病及び他の障害の治療のための組成物及び方法
CN115666564B (zh) 在单层片剂中包括氨氯地平、氯沙坦和氯噻酮的预防或治疗心血管系统疾病的药学上组合制剂
US20250367137A1 (en) Phloroglucinol Formulations And Methods Of Use
JP2026513149A (ja) 肝障害を有する患者にパルツソチンを投与するための組成物及び方法
TW202214238A (zh) 在單層片劑中包括氨氯地平、氯沙坦和氯噻酮的預防或治療心血管系統疾病的藥學上組合製劑
HK40082224B (zh) 在单层片剂中包括氨氯地平、氯沙坦和氯噻酮的预防或治疗心血管系统疾病的药学上组合制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250612